Reported 1 day ago
HBM Healthcare Investments AG is considering selling its portfolio company Swixx Biopharma SA, with a potential valuation of around 1.5 billion Swiss francs ($1.7 billion). The Swiss health-care fund is currently assessing interest from potential buyers and may also explore other options, including an IPO or retaining the company longer. Swixx, which specializes in drug distribution for pharmaceutical firms in smaller markets, reported €900 million ($944 million) in sales in 2023 and operates in 44 countries.
Source: YAHOO